Genscript Biotech Enters Sub-License Contract for Anti-PD-1 Single Domain Antibodies

MT Newswires Live11-15

Genscript Biotech (HKG:1548) unit Nanjing Probio Biotech has granted an exclusive, worldwide, and transferable license to LaNova Medicines allowing it to sublicense certain patents related to anti-PD-1 single domain antibodies and providing it with related know-how to manufacture certain molecules, a Friday bourse filing.

LaNova Medicines has confirmed it will make payments to Nanjing Probio Biotech and Zhenjiang Probio Biotech, another unit of the company, under the agreement.

Under the contract, LaNova Medicines will make certain upfront and milestone payments and share a percentage of sublicense revenue with the company.

LaNova Medicines focuses on discovering and developing innovative biologic drugs that transform cancer treatment.

Shares of the company were up over 6% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483345464?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-15 16:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483345464","market":"us","top_or_hot":-1,"title":"Genscript Biotech Enters Sub-License Contract for Anti-PD-1 Single Domain Antibodies","media":"MT Newswires Live","content":"<html><body><p> Genscript Biotech (HKG:1548) unit Nanjing Probio Biotech has granted an exclusive, worldwide, and transferable license to LaNova Medicines allowing it to sublicense certain patents related to anti-PD-1 single domain antibodies and providing it with related know-how to manufacture certain molecules, a Friday bourse filing.</p><p>LaNova Medicines has confirmed it will make payments to Nanjing Probio Biotech and Zhenjiang Probio Biotech, another unit of the company, under the agreement.</p><p>Under the contract, LaNova Medicines will make certain upfront and milestone payments and share a percentage of sublicense revenue with the company.</p><p>LaNova Medicines focuses on discovering and developing innovative biologic drugs that transform cancer treatment.</p><p>Shares of the company were up over 6% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genscript Biotech Enters Sub-License Contract for Anti-PD-1 Single Domain Antibodies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenscript Biotech Enters Sub-License Contract for Anti-PD-1 Single Domain Antibodies\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-15 16:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Genscript Biotech (HKG:1548) unit Nanjing Probio Biotech has granted an exclusive, worldwide, and transferable license to LaNova Medicines allowing it to sublicense certain patents related to anti-PD-...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000306701.USD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2483345464","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483345464","pubTimestamp":1731659592,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Genscript Biotech  unit Nanjing Probio Biotech has granted an exclusive, worldwide, and transferable license to LaNova Medicines allowing it to sublicense certain patents related to anti-PD-1 single domain antibodies and providing it with related know-how to manufacture certain molecules, a Friday bourse filing.LaNova Medicines has confirmed it will make payments to Nanjing Probio Biotech and Zhenjiang Probio Biotech, another unit of the company, under the agreement.Under the contract, LaNova Medicines will make certain upfront and milestone payments and share a percentage of sublicense revenue with the company.LaNova Medicines focuses on discovering and developing innovative biologic drugs that transform cancer treatment.Shares of the company were up over 6% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK1141":"生命科学工具和服务","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK1576":"医药外包概念","BK1583":"高瓴概念","PD":"PagerDuty, Inc.","BK4023":"应用软件","01548":"金斯瑞生物科技","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC"},"translate_title":"金斯瑞生物签订抗PD-1单域抗体分许可合同","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1,"01548":0.9},"content_text":"Genscript Biotech (HKG:1548) unit Nanjing Probio Biotech has granted an exclusive, worldwide, and transferable license to LaNova Medicines allowing it to sublicense certain patents related to anti-PD-1 single domain antibodies and providing it with related know-how to manufacture certain molecules, a Friday bourse filing.LaNova Medicines has confirmed it will make payments to Nanjing Probio Biotech and Zhenjiang Probio Biotech, another unit of the company, under the agreement.Under the contract, LaNova Medicines will make certain upfront and milestone payments and share a percentage of sublicense revenue with the company.LaNova Medicines focuses on discovering and developing innovative biologic drugs that transform cancer treatment.Shares of the company were up over 6% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483345464"}